Medicus Pharma Ltd. (NASDAQ:MDCX – Get Free Report) fell 4.4% on Friday . The company traded as low as $3.16 and last traded at $3.29. 27,849 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 54,424 shares. The stock had previously closed at $3.44.
Wall Street Analysts Forecast Growth
MDCX has been the subject of a number of research reports. Brookline Capital Management upgraded shares of Medicus Pharma to a “strong-buy” rating in a research note on Monday, December 23rd. Maxim Group initiated coverage on shares of Medicus Pharma in a research note on Tuesday, December 17th. They set a “buy” rating and a $10.00 target price for the company.
View Our Latest Stock Analysis on Medicus Pharma
Medicus Pharma Stock Performance
Institutional Investors Weigh In On Medicus Pharma
An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new stake in shares of Medicus Pharma Ltd. (NASDAQ:MDCX – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma accounts for about 1.3% of Interchange Capital Partners LLC’s portfolio, making the stock its 15th largest holding. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma as of its most recent filing with the SEC.
Medicus Pharma Company Profile
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
- Five stocks we like better than Medicus Pharma
- Expert Stock Trading Psychology Tips
- How to Build the Ultimate Everything ETF Portfolio
- Industrial Products Stocks Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.